• 1
    Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005;106:1449.
  • 2
    Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008;28:2126.
  • 3
    Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008;199:122.
  • 4
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:9921005.
  • 5
    Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:153944.
  • 6
    Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:7329.
  • 7
    Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20(1):IXXIV.
  • 8
    Kloosterman GJ. On intrauterine growth; the significance of prenatal care. Int J Gynaecol Obstet 1970;8:895912.
  • 9
    Royston P, Thompson SG. Model-based screening by risk with application to Down’s syndrome. Stat Med 1992;11:25768.
  • 10
    Cuckle HS, Arbuzova S. Multimarker maternal serum screening for chromosomal abnormalities. In: MilunskiA, editor. Genetic Disorder and the Fetus: Diagnosis, Prevention, and Treatment. Baltimore: Johns Hopkins University Press; 2004. pp. 795835.
  • 11
    Cuckle HS, Wald NJ. Principles of screening. In: WaldN, LeckI, editors. Antenatal & Neonatal Screening, 2nd edn. Oxford: Oxford University Press; 2000. pp. 322.
  • 12
    Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down’s syndrome in early pregnancy. BMJ 1988;297(6653):8837.
  • 13
    Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004;25:60822.
  • 14
    Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem 2004;271:106578.
  • 15
    Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007;197:357.
  • 16
    Livingston JC, Haddad B, Gorski LA, Neblett P, Ahokas RA, Ramsey R, et al. Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol 2001;184: 121820.
  • 17
    Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:923.
  • 18
    Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21:27987.
  • 19
    Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008; 112:108290.